HOME AGENDA SPONSORS REGISTRATION CONTACT US
 

Evaluation

Please click on this LINK to complete the Cardiology for the Practitioner Evaluation Survey.

Upon completion the Certificate of Attendance will be emailed to you

Please note: Only those that registered and attended the webinar will receive the certificate of attendance after completing the evaluation survey

 

Learning Objectives:
Upon completion of this meeting, participants will have increased ability to:
  1. Recognize the risks and benefits and implement strategies for managing patients with complex cardiovascular disease (CAD) including patients with atrial fibrillation (AF), hypertension, diabetes and heart failure.
  2. Evaluate risks and benefits of DAPT post PCI and long term as secondary prevention.
  3. Implement strategies for appropriate stroke and systemic embolism prevention in patients with atrial fibrillation.
  4. Evaluate efficacy of antiplatelet and antithrombotic therapies in preventing adverse cardiovascular outcomes in patients with CAD and AF.
  5. Translate evidence-based strategies for prevention, screening and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
  6. Identify evidence based management of cardiovascular morbidity and mortality among patients with diabetes.
  7. Identify evidence based management of cardiovascular morbidity and mortality among patients with heart failure.
  8. Identify evidence based management of lipid lowering among patients with established cardiovascular disease.

 

 


Cardiology for the Practitioner
Virtual Meeting
Saturday, April 30, 2022

AGENDA
8:00 am Welcome and Introduction Howard Leong-Poi, MD
   
Session I:
Chair: Akshay Bagai, MD
8:10 Thresholds instead of targets in lipid lowering and prevention in ASCVD
Interactive Learning:10 min Q & A by use of on-line polling
Beth Abramson, MD
   
8:35 Evidence based choices in lipid lowering beyond statin
Interactive Learning:10 min Q & A by use of on-line polling
Anatoly Langer, MD
   
9:00 Beyond LDL-C lowering: anti-inflammatory therapies for CAD
Interactive Learning:10 min Q & A by use of on-line polling
Shaun Goodman, MD
   
9:25 Type 2 Diabetes Mellitus and ASCVD: SGLT2 inhibitors, GLP-1 receptor agonists, or both?
Interactive Learning:10 min Q & A by use of on-line polling
Kim Connelly, MD
   
9:50 Interactive Learning: Panel Discussion with audience, moderated session, Q&A augmented by use of on-line chat, Q&A or raising of hand Faculty
   
10:10 Break  
Session II:
Chair: Kaja Konieczny, MD
10:25

Which AF requires treatment and which treatment?
Interactive Learning:10 min Q & A by use of on-line polling

Paul Dorian, MD
   
10:50

What is the role for aspirin in CVD prevention?
Interactive Learning:10 min Q & A by use of on-line polling

Andrew Yan, MD
   
11:15 Peripheral artery disease: Underappreciated and undertreated
Interactive Learning:10 min Q & A by use of on-line polling
Charles de Mestral, MD
   
11:40 Diagnosis and management of patients with chest pain
Interactive Learning:10 min Q & A by use of on-line polling
Yin Ge, M
   
12:05 Interactive Learning: Panel Discussion with audience, moderated session, Q&A augmented by use of on-line chat, Q&A or raising of hand Faculty
12:25 Break  
Session III:
Chair: Geraldine Ong, MD
12:40 What is the new standard of care in hypertension?
Interactive Learning:10 min Q & A by use of on-line polling
Chi-Ming Chow, MD
   
1:05 Evidence-based HFrEF management: I need two hands to count
Interactive Learning:10 min Q & A by use of on-line polling
Susanna Mak, MD
   
1:30

Evidence-based management of HFpEF: my hands are free
Interactive Learning:10 min Q & A by use of on-line polling

Gordon Moe, MD
   
1:55

Interactive Learning: Panel Discussion with audience, moderated session, Q&A augmented by use of on-line chat, Q&A or raising of hand

Faculty
2:15 CLOSE